恶性肿瘤患者血清sIL－2R临床意义的评估

Significance of Serum Soluble Interleukin-2 Receptor in Cancer Patients

用ＥＬＩＳＡ法测定３６５例肿瘤患者（包括胃癌、肝癌、胰腺癌、结肠癌、乳腺癌、卵巢癌、肺癌、恶性淋巴瘤、白血病）和２３０例相关脏器的良性疾病患者以及５１名健康人的血清ｓＩＬ－２Ｒ浓度，发现恶性肿瘤患者血清ｓＩＬ－２Ｒ水平明显高于良性疾病患者和健康人对照组（Ｐ＜０．００１），伴转移患者的ｓＩＬ－２Ｒ升高更明显，与不伴转移者相比，差异显著（Ｐ＜０．００１）。作为免疫活性标志，血清ｓＩＬ－２Ｒ可以作为评估肿瘤发生和检测复发的辅助手段。

Serum sIL-2R level was measured by ELISA in 365 patients with cancers, such as gastric, hepatic, pancreatic, colonic, mammary, ovarian, pulmonary cancer, malignant lymphoma and leukemia as well as in 230 patients with benign diseases and in 51 healthy subjects. The mean serum levels were significantly elevated in patients with cancers of various organs(P<0. 001).Patients with metastasis had even higher values than those without(P< 0. 001). Recurrent or persistant elevation after resection indicated residual focus or recurrence. It is believed that sIL-2R may be a 42KD segment piece of Tac antigen shedded from IL-2R of normal mononuclear cells as well as from surfaces of malignant cells.It' s elevation can be taken as a token of host biological response as well as an active marker of malignancy.